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Abstract
Autonomic imbalance with increased adrenergic and reduced parasympathetic activity is
involved in the development and progress of heart failure (HF). Experimental data have
demonstrated that stimulation of the vagus nerve is able to reverse ventricular remodeling of
the failing heart. There is also evidence that increasing parasympathetic activity may stimulate
the production of nitric oxide, and reduce the devastating inflammatory process involved in
HF. Vagus nerve stimulation (VNS) has been successfully applied for many years to treat drug
resistant epilepsy. The first study of right vagus stimulation in patients with advance HF has
proven the feasibility and safety of this new approach. Long term follow-up of increased vagal
tone over 12 months with a specially designed stimulating system (CardioFit, BioControl,
Yehud, Israel) has demonstrated that symptoms of HF can be significantly diminished, left
ventricular ejection fraction increased, and ventricular volumes reduced. These recently pub-
lished data are very promising and may offer another approach for patients with advanced HF
already treated with optimal medical therapy. A prospective randomized trial with a larger
patient cohort is needed to confirm these beneficial results of VNS. (Cardiol J 2010; 17, 6: 638–
–643)
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Introduction
Despite significant progress in medical treat-
ment of congestive heart failure (HF) in recent
years, particularly with consequent prescription of
angiotensin-converting enzyme inhibitors, angio-
tensin receptor blockers, beta-blocker and aldoster-
one antagonists mortality remains high once the
patient has reached an advanced stage of HF [1].
Treatment of the failing heart must relieve disabling
symptoms, should be directed to the underlying
disease, and will concentrate on strategies to inter-
rupt the ventricular remodeling process. With car-
diac resynchronization therapy a very successful
non-medical approach using biventricular pacing
was added to the armamentarium for HF treatment
although limited to patients with a wide QRS com-
plex and mechanical dyssynchrony. New techniques
rather than new drugs are on the horizon to treat
or reverse the progressively impairing structural
changes of the failing myocardium.
Autonomic imbalance
There is ample experimental and clinical proof
that HF goes along with autonomic imbalance de-
monstrating increased sympathetic activity and a re-
duced parasympathetic activation [2–4]. In the ear-
ly stage of myocardial injury and hemodynamic im-
pairment increased sympathetic activity may be
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beneficial to maintain cardiac output and support
myocardial performance. However, in the long-term
run the compensatory preponderance of increased
beta-adrenergic stimulation leads to deterioration
of ventricular performance, structural remodeling
with increased apoptosis of myocytes, deposition of
fibrous tissue leading to ventricular dilatation, and
a higher risk of electrical instability [5, 6]. At the
same time parasympathetic activation with its bene-
ficial effects is significantly attenuated with pro-
gressing HF, measurable particularly by loss of
heart rate (HR) control.
The interaction between the sympathetic and
parasympathetic system with both afferent and ef-
ferent fibers is rather complex and far from being
completely understood. Evidence exists that the
parasympathetic system is involved in the regula-
tion of endothelial nitric oxide (NO) expression, and
dysregulation of NO pathways due to reduced va-
gal ganglionic transmission impairs contractility and
cardiac function, leading to worsening of HF [7].
Another important finding is the fact that parasym-
pathetic activity can inhibit inflammatory  cytokine
release and may help to prevent tissue injury and
cell death by its anti-inflammatory response [8, 9].
Therefore diminished vagal activity will promote
harmful cytokine over-production.
Clinical evaluation of reduced parasympathe-
tic activity in HF patients is difficult and can only be
done indirectly by observation of increased resting
HR, diminished HR variability, particularly the high
frequency component, or the ratio of low frequen-
cy to high frequency components. Another para-
meter which reflects vagal activity is the barore-
ceptor sensitivity [10]. Baroreceptor sensitivity is
found significantly depressed in HF and was found
as a predictor of increased risk of ventricular tachy-
cardia/ventricular fibrillation and overall mortality
(ATRAMI study) [11, 12].
Heart failure is closely linked with the occur-
rence of life-threatening ventricular tachyarrhyth-
mias, promoted by increased sympathetic activity,
reduced parasympathetic tone or both. Experimen-
tal animal data in conscious dogs clearly demon-
strate that increasing vagal tone by means of right
vagus nerve stimulation (VNS) can prevent ventri-
cular tachyarrhythmias in a model with healed myo-
cardial infarction, exercise testing and intermittent
ischemia [13]. Of note is the fact that the observed
anti-fibrillatory effect was independent from HR
reduction.
In summary currently available experimental
and clinical data indicate that HF is associated with
reduced vagal activity. Withdrawal of parasympa-
thetic tone increases propensity to life-threaten-
ing arrhythmias and promotes structural remode-
ling. Therefore it seems only logical that VNS
may become another approach to treat HF and to
reverse ventricular remodeling.
Experimental results
of vagus nerve stimulation
The first important animal model of VNS in HF
was reported in 2004 by Li et al. [14]. Rats deve-
loped HF after anterior myocardial infarction and
were randomized to VNS or to a sham stimulated
group. Stimulation was performed for 10 s every
minute with stimulus intensity able to reduce HR
by 20–30 bpm. A significant improvement of left
ventricular function and decreased mortality from
50% to 14% compared to sham treated animals was
observed after 140 days. Similar beneficial results
of improved left ventricular function with VNS were
found in a canine model of microembolization in-
duced HF [15]. Recently Zhang et al. [16] demon-
strated in another canine model with high rate ven-
tricular pacing induced HF that chronic VNS over
12 weeks was able to reduce ventricular volumes
and increased left ventricular ejection fraction
(LVEF) significantly. Heart rate reduction did not
play a role in this model since both, treated and con-
trol group were constantly paced at the same rate.
Important findings were presented by Sabbah et al.
[17] with their microembolization HF model. Low
intensity vagus stimulation with no HR decrease
improved left ventricular function, and showed sig-
nificant decrease of harmful biomarkers of HF.
Vagus nerve stimulation for epilepsy
Vagus nerve stimulation for drug refractory
seizures in epilepsy patients was introduced more
than 20 years ago, and its safety and efficacy has
been described by various authors [18, 19]. The
Cyberonics vagus nerve stimulator system (Cy-
beronics Inc. Houston, TX, USA) consists of an
implantable pulse generator and a helical bipolar
lead attached to left cervical portion of the vagus
nerve. Until today about 50,000 patients have been
treated for epilepsy with this device. Recently VNS
has also been applied for treatment of drug resis-
tant depression [20].
Vagus nerve stimulation
The neurostimulator (CardioFit 5000, BioCon-
trol Medical, Yehud, Israel) delivers low-current
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electrical pulses. The right vagus nerve is exposed
through a latero-cervical incision under general
anesthesia; the generator is implanted subcutane-
ously in the right sub-clavicular region just like
a regular pacemaker (Fig. 1). The device senses the
HR by means of a right ventricular electrode. Pul-
ses are delivered to the right vagus nerve via a sti-
mulation lead that contains an asymmetric bipolar
multi-contact cuff electrode placed around the nerve
about 2–3 cm below the carotid artery bifurcation.
Pulses are delivered at a programmable preset de-
lay from the R-wave. If the HR drops below a pro-
grammed rate, stimulation is interrupted. Action
potentials in the vagus nerve are produced by ca-
thodic induction with simultaneously applying
asymmetric anodal blocks activating more efferent
than afferent vagus-nerve fibers. A 3 week up-ti-
tration phase to reach the maximum tolerable cur-
rent amplitude (from 0.5 to 5.0 amp) begins about
3–4 weeks after device implantation. Stimulus
strength is limited by patient symptoms (pain,
cough, dysphonia) and HR dropping. The relation-
ship between stimulation “on” and stimulation “off”
will be progressively prolonged to a maximum of
10 s “on” and 30 s “off”, depending on the patient’s
tolerance. Heart rate reduction with nerve stimu-
lation should be limited to not more than 10 bpm
below the basic HR.
With careful up-titration of vagus stimulation
unpleasant side effects can be diminished. The most
frequent adverse effects are mild cough, particularly
at the beginning of the stimulus strength up-titra-
tion (about 50%), pain at the nerve stimulation side
(about 50%) or at the right mandible region, voice
alteration or dysphonia (about 20%). Dramatic HR
decrease can hardly occur because nerve stimula-
tion is interrupted with significant (> 10 bpm) drop
of HR.
First human study with
vagus nerve stimulation
Based on the available impressive results of
VNS in animal models of HF, Schwartz et al. [21]
were the first to launch a single center pilot study
with a single arm open-label intervention to dem-
onstrate the feasibility, tolerability and safety of
VNS in patients with advanced HF. The first part
of this study enrolled only 8 patients, later the phase
II study was extended to a multi-center phase II trial
with altogether 32 patients. The secondary endpoint
of this small study looked also at clinical effective-
ness of VNS over 6 months with optional extended
follow-up over 1 year.
After 6 month a moderate but significant de-
crease of the resting HR was noted in 29 patients.
Figure 1. Design of the CardioFit vagus-nerve stimulation system. Upper left small panel: Cuff electrode placed
around the right vagus nerve. Left lower panel: CardioFit pulse generator, cuff electrode at the right vagus nerve;
right ventricular sensing lead at the right ventricular apex. Right lower panel: Chest X-ray of a patient with the
CardioFit vagus nerve stimulation system in place. There is a wide loop of the lead from the vagus nerve insertion to
the pulse generator in order to avoid stretching of the electrode with head or shoulder movement (design of the
CardioFit vagus nerve stimulation system [BioControl, Yehud, Israel], reproduced with permission: Conf Proc IEEE
Eng Med Biol Soc, 2009; 1: 2037.
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An improvement of the Minnesota Living with
Heart Failure Quality of life score (MLwHF), an
increase of the 6-minutes walking test and a signi-
ficant reduction of the left ventricular end-systolic
volume (LVESV) were observed. There were few-
er patients in NYHA class III after 6 months, and at
this time the LVEF showed a trend to improvement.
Of the 32 patients enrolled into the study (mean
age 56 years, 94% male, 62% coronary artery dise-
ase) 23 patients were followed over 1 year [22].
Two patients died between 6–12 months, one of end
stage HF, the other one after an acute myocardial
infarction. One patient underwent heart transplant.
Two patients stopped VNS. A significant improve-
ment in NYHA class, an increased 6-minutes walk
test, continued improvement of MLwHF score,
a significant increase of LVEF and LVESV index
were observed. Heart rate variability showed a sig-
nificant increase of pNN50. Resting HR continued
to be slightly but significantly lower than at the time
of VNS onset (Table 1).
How can we explain these findings?
Increased parasympathetic tone with reduced
HR and improved HR variability, even beyond ad-
ditional beta-blocker therapy, may have contribut-
ed to the beneficial results although drop of resting
HR was rather moderate over the course of the
study. Most likely an actively produced anti-adre-
nergic effect of VNS may be responsible for the mea-
surable clinical improvement. Although not speci-
fically evaluated, anti-apoptotic and anti-inflamma-
tory effects as well as potentially increased NO
production may all have added to the positive out-
come with impressive improvement of LVEF as
a sign of reverse remodeling.
Indication for vagus nerve stimulation
The first VNS in humans selected patients with
structural heart disease, ischemic as well as non-
-ischemic cardiomyopathy, reduced LVEF and clin-
ical symptoms of advanced HF (NYHA class II–III).
Patients had to be in sinus rhythm with a resting
HR between 60–110 bpm and needed to be on sta-
ble optimal treatment. Excluded were patients with
asthma, chronic obstructive pulmonary disease, his-
tory of gastro-intestinal bleeding, peptic ulcer, insu-
lin-dependent diabetes mellitus, glaucoma, and sig-
nificantly prolonged AV-conduction (PR > 240 ms).
All enrolled patients were no candidates for cardiac
resynchronization therapy.
Since future trials will need randomization and
longer follow-up time in order to evaluate the clinical
effectiveness of chronic VNS, it seems advisable to
enroll patients with stable HF conditions but in a less
advanced stage of failure (i.e. NYHA class IV should
be excluded). Before we know the results of long-term
parasympathetic stimulation on the AV node, patients
with atrial fibrillation should also be excluded. It
would be interesting, however, to find out if VNS is
able to prevent occurrence of atrial fibrillation, or if
increased vagus tone may promote the onset of atri-
al fibrillation because of potential inhomogeneous
shortening of the atrial refractory period.
Potential VNS patients are also potential can-
didates for implantable cardioverter-defibrillator
(ICD) therapy. In fact, more than 50% of the en-
rolled patients in the initial study had previous ICD
implantation, and ICD shocks occurred during fol-
low-up. This indicates that patients for VNS should
not be excluded because of their implanted ICD.
There were no interactions noted between the two
electrical devices.
Table 1. Long-term follow-up of 23 patients (modified from [22]).
Variable Baseline 12 months P
Heart rate [bpm] 85 ± 14 76 ± 11 0.003
Heart rate variability (pNN50) 4.6 (1.8–8.4) 7.4 (3.2–24.0) 0.001
6-minutes hall walk test [m] 405 ± 92 472 ± 139 0.012
LVESVI [mL/m2] 100 ± 40 80 ± 44 0.009
Left ventricular ejection fraction (%) 21.1 ± 7.5 34.1 ± 12.5 < 0.0001
MLwHF score 47 ± 19 30 ± 24 0.001
NYHA I/II/III/IV 0/14/9/0 10/10/3/0 < 0.001
LVEDVI [mL/m2] 126 ± 47 118 ± 56 0.36
Seven parameters were found significantly improved after 12 month of vagus-nerve stimulation, except the left ventricular end-diastolic volume
index (LVEDVI); LVESVI — left ventricular end-systolic volume index; MLwHF score — Minnesota Living with Heart Failure Quality of life score
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Vagus nerve stimulation can be considered as
“add-on” therapy to optimal medical therapy for HF.
It may not be restricted for any specific underlying
disease process except significant valve disease or
an acute coronary syndrome. Its effect in patients
with advanced renal disease or insulin-dependent
diabetes mellitus needs to be investigated in more
detail. Although experimental data demonstrated
anti-fibrillatory effects on the ventricular level,
a significant anti-arrhythmic effect of VNS in pa-
tients with HF has to be assessed in the future.
Unanswered questions
The most important question in VNS relates
to the mechanism of its beneficial effect. Heart rate
reduction may be important and reflects the anti-
adrenergic effect of increased vagus tone. Howev-
er, recent experimental data and the clinical out-
come of the first application in patients demonstrate
that the advantageous effect is measurable even
without clinically relevant HR reduction. The im-
proved HR variability clearly shows that there is
increased parasympathetic activity. The acute ef-
fectiveness of VNS is difficult to asses, and there-
fore prediction of response becomes uncertain. An
effective anti-apoptotic mechanism, an increased
production of endothelial NO and the anti-inflam-
matory effect may well be the major contributor to
the observed reverse remodeling action of VNS.
The most effective and tolerable dose of VNS
as well as the optimal stimulation mode still needs
to be determined. It is unclear if exclusively effer-
ent or both types, efferent and afferent vagus fibers
need to be stimulated. It may be technically chal-
lenging to separate the two types of fibers with the
current or even future stimulation devices. It is also
unanswered if the right vagus nerve is more impor-
tant than the left sided nerve, and if even better
results may be achieved with both nerves stimu-
lated, although this may be technically more diffi-
cult to do. Will it be more appropriate to apply con-
tinuous stimulation instead of pulse-synchronous
stimuli? The optimal number of pulses per cycle,
the stimulus amplitude and the maximum current
needs to be established. We don’t know the most
appropriate relationship between stimulation time
and stimulation pause. Which is the best titration
parameter, either HR reduction or tolerable symp-
toms such as pain or cough?
The device that was used for the first patient
study needed a right ventricular sensing lead, but
it may not even need an extra intra-cardiac lead at
all? All these questions and uncertainties have to




The important physiologic role of autonomic
balance for the heart, and the possibility to restore
its imbalance by increasing the vagus tone through
electrical stimulation has been well established,
particularly for patients with HF, not yet, howev-
er, for better arrhythmia control.
Non-pharmacologic treatment of HF as “add-
on” approach has opened a whole new field of re-
search and clinical practice [23]. Large experience
and excellent results are available with cardiac re-
synchronization therapy. Cardiac contractility modu-
lation has been introduced for HF treatment; how-
ever, a broad application with this technique is still
missing [24]. Carotid baroreceptor stimulation for
the treatment of drug-resistant hypertension seems
to be another promising electrical approach [25].
A different place to increase parasympathetic activi-
ty in order to have a beneficial impact on HF and/or
ventricular arrhythmias is the spinal cord stimula-
tion. Studies using this technique have started, but
results in patients with HF are not yet available [26].
The recently published data of the first phase
II study of VNS are quite promising. A larger multi-
center randomized trial to confirm the initial results
will be launched soon, and technical progress of
nerve stimulators is predictable. New experimen-
tal results on the molecular and cellular level of
remodeling predict the potential benefit of VNS in
patients [27]. Questions how to transform this ap-
proach into a simple to do therapy for a broad spec-
trum of HF patients, how to predict responders or
non-responders, and how to make it a cost-effec-
tive treatment need to be answered in the future.
Conclusions
The pathophysiologic mechanism of autonomic
imbalance and the beneficial effect of VNS to correct
it have long been recognized. First clinical data are
now available. They confirm the feasibility, safety and
tolerability of VNS. Although the results of the clini-
cal effectiveness of the new approach are derived
from a small group of patients, they are promising,
and will open a new field of clinical research in order
to improve HF symptoms, to reverse ventricular
remodeling, and to prevent HF progression.
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